Last reviewed · How we verify
NCT05651113
The Experience of Screening for SCID
trial testing SCID Screening in Severe Combined Immunodeficiency in 90 participants. Currently enrolling.
31 March 2029
Quick facts
| Lead sponsor | King's College London |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 90 |
| Start date | 9 November 2022 |
| Primary completion | 31 March 2029 |
| Estimated completion | 31 March 2029 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- SCID Screening — full drug profile →
Conditions studied
- Severe Combined Immunodeficiency — all drugs for Severe Combined Immunodeficiency →
Sponsor
King's College London
Who can join
18 and older, any sex, with Severe Combined Immunodeficiency. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This project will evaluate the impact of including Severe Combined Immunodeficiency into the newborn bloodspot screening panel. It will recruit parents and health professionals primarily from the sites where this new form of screening is being trialled well as additional sites where clinicians will be involved in the care of these babies and comparator groups are needed. The proposed work will consist of two work packages. The first, a mixed-methods study conducted with families from the point of screening information being returned through to the child's fifth birthday. The second, a qualitative interview study conducted with health professionals during the clinical evaluation phase of the national pilot programme.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05651113
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Severe Combined Immunodeficiency
Currently open trials in the same condition.
- NCT03597594 — Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Comb · Phase 1, PHASE2 · active not recruiting
- NCT00055172 — Genetic Basis of Immunodeficiency · recruiting
Other King's College London trials
Trials by the same sponsor.
- NCT07357064 — Professional Decision Making in Childbirth. · not yet recruiting
- NCT07341087 — Skin Inflammation in Perimenopause: A Probiotic Intervention Proof of Concept Trial · NA · recruiting
- NCT07228962 — Cutaneous Biomarkers in Atopic Eczema Using a Non-Invasive Micro-Suction Device in Babies · not yet recruiting
- NCT07365722 — Comparison of Two Non-surgical Procedure to Manage Gum Disease Around Implants. · NA · not yet recruiting
- NCT07378488 — Dance/Movement Therapy for Functional Neurological Disorder · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05651113 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by King's College London
- Last refreshed: 14 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05651113.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing